Literature DB >> 20161481

Disease Restaging and Diagnosis of Recurrent and Metastatic Disease Following Primary Therapy with FDG-PET Imaging.

William B Eubank, Jean H Lee, David A Mankoff.   

Abstract

Entities:  

Year:  2009        PMID： 20161481      PMCID： PMC2794199          DOI： 10.1016/j.cpet.2009.09.001

Source DB:  PubMed          Journal:  PET Clin        ISSN： 1556-8598


× No keyword cloud information.
  83 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer.

Authors:  T S Kim; W K Moon; D S Lee; J K Chung; M C Lee; Y K Youn; S K Oh; K J Choe; D Y Noh
Journal:  World J Surg       Date:  2001-07       Impact factor: 3.352

3.  Powerful prognostic stratification by [18F]fluorodeoxyglucose positron emission tomography in patients with metastatic breast cancer treated with high-dose chemotherapy.

Authors:  Florent Cachin; H Miles Prince; Annette Hogg; Robert E Ware; Rodney J Hicks
Journal:  J Clin Oncol       Date:  2006-05-22       Impact factor: 44.544

4.  Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy.

Authors:  David A Mankoff; Lisa K Dunnwald; Julie R Gralow; Georgiana K Ellis; Aaron Charlop; Thomas J Lawton; Erin K Schubert; Jeffrey Tseng; Robert B Livingston
Journal:  J Nucl Med       Date:  2002-04       Impact factor: 10.057

5.  Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients.

Authors:  J F Vansteenkiste; S G Stroobants; P R De Leyn; P J Dupont; J Bogaert; A Maes; G J Deneffe; K L Nackaerts; J A Verschakelen; T E Lerut; L A Mortelmans; M G Demedts
Journal:  J Clin Oncol       Date:  1998-06       Impact factor: 44.544

6.  Comparison between positron emission tomography using 2-[fluorine-18]fluoro-2-deoxy-D-glucose, conventional imaging and computed tomography for staging of breast cancer.

Authors:  S Mahner; S Schirrmacher; W Brenner; L Jenicke; C R Habermann; N Avril; J Dose-Schwarz
Journal:  Ann Oncol       Date:  2008-03-19       Impact factor: 32.976

7.  Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC).

Authors:  Jennifer R Bellon; Robert B Livingston; William B Eubank; Julie R Gralow; Georgiana K Ellis; Lisa K Dunnwald; David A Mankoff
Journal:  Am J Clin Oncol       Date:  2004-08       Impact factor: 2.339

8.  [18F]FDG in recurrent breast cancer: diagnostic performances, clinical impact and relevance of induced changes in management.

Authors:  Dany Grahek; Françoise Montravers; Khaldoun Kerrou; Nicolas Aide; Jean-Pierre Lotz; Jean-Noël Talbot
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

9.  Impact of PET/CT in comparison with same day contrast enhanced CT in breast cancer management.

Authors:  Elena Piperkova; Barbara Raphael; Mustafa E Altinyay; Ivan Castellon; Richard Libes; Nick Sandella; Sherif Heiba; Hussein Abdel-Dayem
Journal:  Clin Nucl Med       Date:  2007-06       Impact factor: 7.794

10.  Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer.

Authors:  J A Schneider; C R Divgi; A M Scott; H A Macapinlac; A D Seidman; S J Goldsmith; S M Larson
Journal:  J Nucl Med       Date:  1994-11       Impact factor: 10.057
View more
  1 in total

Review 1.  PET/CT and breast cancer.

Authors:  C Hegarty; C D Collins
Journal:  Cancer Imaging       Date:  2010-10-04       Impact factor: 3.909
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.